Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells

Anti-Cancer Drugs

Volumn 19, Issue 7, 2008, Pages 681-688

  Roforth, Matthew M ^a   Tan, Chalet ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MERCER UNIVERSITY   (United States)

Author keywords

17 allylamino 17 demethoxygeldanamycin; Akt; Extracellular signal regulated kinase 1 2; Heat shock protein 90; Rapamycin; The mammalian target of rapamycin

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN D1; CYCLIN E; HEAT SHOCK PROTEIN 90; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; S6 KINASE; SERINE; SOMATOMEDIN C RECEPTOR; TANESPIMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM; PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEAT SHOCK RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN E; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 51049093831     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283067681     Document Type: Article

References (24)

1. Shaw R, Cantley L. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-430.
2. Inoki K, Li Y, Zhu T, Wu J, Guan K. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648-657.
3. Ma L, Chen Z, Erdjument-Bromage H, Tempest P, Pandolfi P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121:179-193.
4. Kim D, Sarbassov D, Ali S, King J, Latek R, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163-175.
5. Yu K, Toral-Barza L, Discafani C, Zhang W, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-258.
6. Chan S, Scheulen M, Johnston S, Mross K, Cardoso F, Dittrich C, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-5322.
7. Sun S, Rosenberg L, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-7058.
8. O'Reilly K, Rojo F, She Q, Solit D, Mills G, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508.
9. Solit D, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 2006; 6:1205-1214.
10. Pick E, Kluger Y, Giltnane J, Moeder C, Camp R, Rimm D, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007; 67:2932-2937.
11. Solit D, Ivy S, Kopil C, Sikorski R, Morris MJ, Slovin SF, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007; 13:1775-1782.
12. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem 1989; 182:16-19.
13. Harrington L, Findlay G, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166:213-223.
14. Whitesell L, Lindquist S. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5:761-772.
15. Pollak M, Schernhammer E, Hankinson S. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-518.
16. Sivaraman V, Wang H, Nuovo G, Malbon C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997; 99:1478-1483.
17. Bjornsti M, Houghton P. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335-348.
18. Rojo F, Najera L, Lirola J, Jimé nez J, Guzmán M, Sabadell M, et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007; 13:81-89.
19. Ohji G, Hidayat S, Nakashima A, Tokunaga C, Oshiro N, Yoshino K, et al. Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin. J Biochem 2006; 139:129-135.
20. Sekulić A, Hudson C, Homme J, Yin P, Otterness D, Karnitz L, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000; 60:3504-3513.
21. Chiang G, Abraham R. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005; 280:25485-25490.
22. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005; 23:4215-4224.
23. Malumbres M, Barbacid M. Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 2006; 9:2-4.
24. Keyomarsi K, Tucker S, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566-1575.